Analyst Price Targets — APLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 9:18 am | — | Wells Fargo | $41.00 | $40.87 | TheFly | Apellis downgraded to Equal Weight from Overweight at Wells Fargo |
| January 27, 2026 9:23 pm | — | Barclays | $24.00 | $21.81 | TheFly | Apellis initiated with an Equal Weight at Barclays |
| January 20, 2026 11:06 am | — | Wells Fargo | $26.00 | $19.94 | TheFly | Apellis price target lowered to $26 from $29 at Wells Fargo |
| January 13, 2026 12:54 pm | — | Cantor Fitzgerald | $35.00 | $23.20 | TheFly | Apellis price target lowered to $35 from $39 at Cantor Fitzgerald |
| January 12, 2026 6:45 pm | — | Goldman Sachs | $19.00 | $23.20 | StreetInsider | Goldman Sachs on Apellis Pharmaceuticals (APLS): 'we see limited near-term growth levers' |
| December 19, 2025 12:47 pm | — | Stifel Nicolaus | $48.00 | $24.48 | TheFly | Apellis price target lowered to $48 from $55 at Stifel |
| November 3, 2025 11:36 am | Graig Suvannavejh | Mizuho Securities | $19.00 | $21.47 | StreetInsider | Apellis Pharmaceuticals (APLS) PT Lowered to $19 at Mizuho |
| October 31, 2025 11:25 am | — | Robert W. Baird | $52.00 | $20.73 | TheFly | Apellis price target raised to $52 from $50 at Baird |
| October 31, 2025 10:05 am | — | H.C. Wainwright | $45.00 | $20.73 | TheFly | Apellis price target lowered to $45 from $57 at H.C. Wainwright |
| October 29, 2025 12:46 pm | — | Mizuho Securities | $24.00 | $29.70 | TheFly | Apellis price target raised to $24 from $22 at Mizuho |
Latest News for APLS
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 billion earlier this year.
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 B
[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNAÂ (talazoparib), an oral poly ADP-ri
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APLS.
U.S. House Trading
No House trades found for APLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.